FDA Eyes Sanofi Antibiotic Over Safety Concerns
The U.S. Food and Drug Administration has asked a joint panel of outside experts to turn the spotlight on a bronchitis treatment marketed by pharmaceutical giant Sanofi-Aventis SA amid concerns over...To view the full article, register now.
Already a subscriber? Click here to view full article